This trial is evaluating whether Brentuximab Vedotin will improve 1 primary outcome, 4 secondary outcomes, and 2 other outcomes in patients with CD30-Positive Neoplastic Cells Present. Measurement will happen over the course of At 4 months.
This trial requires 55 total participants across 1 different treatment group
This trial involves a single treatment. Brentuximab Vedotin is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"Findings from a recent study confirms the unpredictable nature of mesothelioma therapy. However, some stage 5B patients could survive longer than two years. The addition of mitoxantrone to platinum-based chemotherapy does not appear to impact survival." - Anonymous Online Contributor
"Mesothelioma, in the United States, affects more than 11,000 new cases each year, and more people are diagnosed with mesothelioma each year than with [lung cancer](https://www.withpower.com/clinical-trials/lung-cancer)s. (Source: American Cancer Society. 1994. Mesothelioma Update. Cancer Facts & Figures 1994) http://www.asmeso-info.org/mesothelioma_updat.html; accessed July 11, 1999." - Anonymous Online Contributor
"The signs of mesothelioma (ataxia, pain, dyspnea, hematemesis) appear similar to other non-malignant conditions. The signs of pleural metastases are the most common presenting features of mesothelioma." - Anonymous Online Contributor
"The most common treatments for mesothelioma include non-specific chemotherapy, surgery, radiation therapy and targeted therapy. Because of the broad range of treatments, it is important to consider these when selecting management of this common cancer." - Anonymous Online Contributor
"Mesothelioma is a sub-class of malignant mesothelial tumours of the ovarian and pleural surfaces. It is considered to be the most aggressive cancer of the peritoneal cavity and is one of the most lethal diseases in the world. Around 30,000 cases a year are diagnosed, more than half occurring in women. Risk factors include heavy exposure to asbestos dust and smoking. Asbestos was used for over 200 years as a filler for many manufactured products, such as shoes, mattresses, textiles, automotive parts and automobile springs. In many developing countries, asbestos is still used in many industries such as construction and in the manufacture of brake pads and brakes." - Anonymous Online Contributor
"We found a higher rate of asbestos exposure compared with that of lung cancer; however, no significant differences were found between the exposed and unexposed groups. Recent findings show a significant association between asbestos or other chemicals used to treat asbestos and development of mesothelioma." - Anonymous Online Contributor
"The drug combination of brentuximab vedotin with docetaxel improved OS and PFS compared with a placebo. Recent findings suggest that the addition of BV to taxane chemotherapy can be effective in the treatment of patients who have progressive or relapsed/refractory MM who failed previous therapies." - Anonymous Online Contributor
"Given that patients who receive vedotin will usually also receive chemotherapy, brentuximab vedotin might improve overall survival in pleural mesothelioma and possibly lung cancers, due to enhanced tumor lysis and cytotoxicity as well as an increased number of tumor cell deaths." - Anonymous Online Contributor
"Brentuximab vedotin was approved by the FDA for the treatment of relapsed and/or refractory systemic therapy-naive patients with metastatic melanoma (in combination with dacarbazine) and was approved by the EMA for the same indications. An open-label, randomized phase 3 trial of (brentuximab vedotin 240 mg, three cycles of iv (brentuximab vedotin 240 mg, three consecutive consecutive cycles in 8 weeks) monthly from 2 October 2014 to 26 February 2019 in patients with metastatic clear cell renal cell carcinoma (mRCC) or locally advanced mRCC who are chemotherapy-naive." - Anonymous Online Contributor
"Mesothelioma is a rapidly growing tumor. It is not only a serious tumor of the lung with a mortality rate of 28%, with poorer prognosis (as compared to other cancers of the lung) when the disease is diagnosed prior to being encapsulated, or has spread to other parts of the chest. If mesothelioma has been diagnosed with some aggressiveness of late stage of the disease is diagnosed, then the survival rate drops to a similar level as for lung sarcoma. Mesothelioma is a cancer with a bad survival rate which is influenced by patient's gender, age, and the stage of the disease when it was diagnosed, so it is better to check its stage and its aggressiveness before treatment." - Anonymous Online Contributor
"Data from a recent study are consistent with an autosomal-dominant inheritance of a mutated gene(s) or genes associated with mesothelioma, especially for families with a history of pleural mesothelioma." - Anonymous Online Contributor